JP2015532296A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015532296A5 JP2015532296A5 JP2015535036A JP2015535036A JP2015532296A5 JP 2015532296 A5 JP2015532296 A5 JP 2015532296A5 JP 2015535036 A JP2015535036 A JP 2015535036A JP 2015535036 A JP2015535036 A JP 2015535036A JP 2015532296 A5 JP2015532296 A5 JP 2015532296A5
- Authority
- JP
- Japan
- Prior art keywords
- antimetabolite
- pharmaceutically acceptable
- combination
- masitinib
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12306214.3 | 2012-10-04 | ||
| EP12306214 | 2012-10-04 | ||
| PCT/EP2013/070741 WO2014053650A1 (en) | 2012-10-04 | 2013-10-04 | Use of masitinib for treatment of cancer in patient subpopulations identified using predictor factors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015532296A JP2015532296A (ja) | 2015-11-09 |
| JP2015532296A5 true JP2015532296A5 (enExample) | 2016-11-10 |
| JP6234466B2 JP6234466B2 (ja) | 2017-11-22 |
Family
ID=47073382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015535036A Expired - Fee Related JP6234466B2 (ja) | 2012-10-04 | 2013-10-04 | 予測因子を用いて同定された患者サブ集団における癌の処置のためのマシチニブの使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10238649B2 (enExample) |
| EP (1) | EP2903616B8 (enExample) |
| JP (1) | JP6234466B2 (enExample) |
| KR (1) | KR102149483B1 (enExample) |
| CN (1) | CN104968347A (enExample) |
| AR (1) | AR092899A1 (enExample) |
| AU (1) | AU2013326463B2 (enExample) |
| BR (1) | BR112015007144A2 (enExample) |
| CA (1) | CA2886979C (enExample) |
| DK (1) | DK2903616T3 (enExample) |
| EA (1) | EA037368B1 (enExample) |
| ES (1) | ES2656640T3 (enExample) |
| IL (1) | IL238107B (enExample) |
| MX (1) | MX369999B (enExample) |
| NZ (1) | NZ706420A (enExample) |
| SG (1) | SG11201502626PA (enExample) |
| SI (1) | SI2903616T1 (enExample) |
| TW (1) | TWI609686B (enExample) |
| WO (1) | WO2014053650A1 (enExample) |
| ZA (1) | ZA201503054B (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015049377A1 (en) * | 2013-10-04 | 2015-04-09 | Ab Science | Method for determining the prognosis of pancreatic cancer |
| JP2017519727A (ja) * | 2014-05-08 | 2017-07-20 | オンコエシックス ゲーエムベーハー | チエノトリアゾロジアゼピン化合物を用いる三種陰性乳癌の治療方法 |
| TWI621434B (zh) * | 2014-10-24 | 2018-04-21 | 朗齊生物醫學股份有限公司 | 千憂解藥物應用於癌症治療 |
| EP3824908A1 (en) | 2015-04-10 | 2021-05-26 | Capsugel Belgium NV | Abiraterone acetate lipid formulations |
| MY199595A (en) | 2016-03-02 | 2023-11-08 | Eisai R&D Man Co Ltd | Eribulin-based antibody-drug conjugates and methods of use |
| EA038531B1 (ru) * | 2016-03-25 | 2021-09-10 | Аб Сьянс | Способ лечения амиотрофного латерального склероза, применение фармацевтической композиции, содержащей мазитиниб |
| CN107267454B (zh) * | 2016-04-07 | 2025-05-23 | 内蒙古原生元生物科技有限公司 | 一种脐血nk细胞的体外扩增方法及其试剂盒与应用 |
| US11040027B2 (en) | 2017-01-17 | 2021-06-22 | Heparegenix Gmbh | Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death |
| KR20190109479A (ko) * | 2017-02-01 | 2019-09-25 | 비욘드스프링 파마수티컬스, 인코포레이티드. | 호중구감소증의 감소 방법 |
| KR102708177B1 (ko) | 2018-01-31 | 2024-09-23 | 데시페라 파마슈티칼스, 엘엘씨. | 위장관 기질 종양의 치료를 위한 병용 요법 |
| CN118903436A (zh) * | 2018-01-31 | 2024-11-08 | 德西费拉制药有限责任公司 | 治疗肥大细胞增多症的组合疗法 |
| US20210398672A1 (en) * | 2018-10-29 | 2021-12-23 | Northwestern University | Big Data-Driven Personalized Management of Chronic Pain |
| WO2020115108A1 (en) * | 2018-12-06 | 2020-06-11 | Sørlandet Sykehus Hf | Egfr inhibitors and their use in the treatment of neuroathic pain |
| WO2020115261A1 (en) * | 2018-12-07 | 2020-06-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and compositions for treating melanoma |
| IL330104A (en) | 2019-03-11 | 2026-08-01 | Deciphera Pharmaceuticals Llc | Crystalline forms of rifatinib |
| HRP20260411T1 (hr) | 2019-08-12 | 2026-05-08 | Deciphera Pharmaceuticals, Llc | Ripretinib za liječenje gastrointestinalnih stromalnih tumora |
| FI4084779T3 (fi) | 2019-12-30 | 2024-12-16 | Deciphera Pharmaceuticals Llc | 1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia |
| CN111759857A (zh) * | 2020-06-30 | 2020-10-13 | 宁波市微循环与莨菪类药研究所 | Gabrd甲基化靶点在制备抗海洛因复吸药物中的应用 |
| ES2963706T3 (es) * | 2021-05-17 | 2024-04-01 | Ab Science | Masitinib para el tratamiento del cáncer de próstata resistente a la castración |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8450302B2 (en) * | 2002-08-02 | 2013-05-28 | Ab Science | 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors |
| MXPA05001277A (es) | 2002-08-02 | 2005-10-06 | Ab Science | 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit. |
| WO2007015935A2 (en) * | 2005-07-29 | 2007-02-08 | Bayer Healthcare Llc | Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy |
| WO2008115300A1 (en) | 2006-12-01 | 2008-09-25 | Apocell, Inc. | C-kit phosphorylation in cancer |
| US8227470B2 (en) | 2007-01-12 | 2012-07-24 | Ab Science | Combination treatment of solid cancers with antimetabolites and tyrosine kinase inhibitors |
| HRP20110709T1 (hr) | 2007-02-13 | 2011-11-30 | Ab Science | Postupak sinteze spojeva 2-aminotioazola kao inhibitora kinaza |
| WO2011056963A1 (en) | 2009-11-04 | 2011-05-12 | The University Of North Carolina At Chapel Hill | Methods and compositions for predicting survival in subjects with cancer |
| TW201130830A (en) * | 2010-02-01 | 2011-09-16 | Ab Science | Combined treatment of pancreatic cancer with gemcitabine and masitinib |
| WO2012170640A1 (en) | 2011-06-07 | 2012-12-13 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for trail-drug combination therapy |
-
2013
- 2013-10-04 AU AU2013326463A patent/AU2013326463B2/en not_active Ceased
- 2013-10-04 NZ NZ706420A patent/NZ706420A/en not_active IP Right Cessation
- 2013-10-04 CN CN201380063241.4A patent/CN104968347A/zh active Pending
- 2013-10-04 WO PCT/EP2013/070741 patent/WO2014053650A1/en not_active Ceased
- 2013-10-04 AR ARP130103596A patent/AR092899A1/es unknown
- 2013-10-04 KR KR1020157011764A patent/KR102149483B1/ko active Active
- 2013-10-04 ES ES13773731.8T patent/ES2656640T3/es active Active
- 2013-10-04 EA EA201500373A patent/EA037368B1/ru unknown
- 2013-10-04 SG SG11201502626PA patent/SG11201502626PA/en unknown
- 2013-10-04 US US14/433,198 patent/US10238649B2/en active Active
- 2013-10-04 MX MX2015004264A patent/MX369999B/es active IP Right Grant
- 2013-10-04 JP JP2015535036A patent/JP6234466B2/ja not_active Expired - Fee Related
- 2013-10-04 TW TW102136110A patent/TWI609686B/zh not_active IP Right Cessation
- 2013-10-04 BR BR112015007144A patent/BR112015007144A2/pt not_active Application Discontinuation
- 2013-10-04 DK DK13773731.8T patent/DK2903616T3/da active
- 2013-10-04 CA CA2886979A patent/CA2886979C/en active Active
- 2013-10-04 EP EP13773731.8A patent/EP2903616B8/en active Active
- 2013-10-04 SI SI201330891T patent/SI2903616T1/en unknown
-
2015
- 2015-04-01 IL IL238107A patent/IL238107B/en active IP Right Grant
- 2015-04-08 ZA ZA2015/03054A patent/ZA201503054B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024010140A (es) | Nuevos metodos. | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| JP2016528301A5 (enExample) | ||
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| JP2017506624A5 (enExample) | ||
| JP2016147915A5 (enExample) | ||
| JP2015524444A5 (enExample) | ||
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| FI3504187T3 (fi) | Pridopidiinin käyttö toiminnallisen heikkenemisen hoitoa varten | |
| JP2016508134A5 (enExample) | ||
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| BR112015025464A2 (pt) | coagonistas do receptor de glp-1/glucagon estáveis, prolongados para uso médico | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| BR112015018168A2 (pt) | inibidores de rock suaves | |
| JP2015523407A5 (enExample) | ||
| TR201909277T4 (tr) | Rasajilinin genişletilmiş salınım formülasyonları ve kullanım alanları. | |
| CL2011002766A1 (es) | Compuestos derivados de carboxamida, inhibidores de calpaina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades neurodegenerativas, alzahimer, dolor, entre otras. | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| RU2017141536A (ru) | Замещенные производные индол-5-ола и их терапевтические применения | |
| MX341660B (es) | Agonista del receptor de ghrelina para el tratamiento de caquexia. | |
| MX2016008027A (es) | Uso de laquinimod para retrasar la evolucion de la enfermedad de huntington. | |
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
| HRP20251123T1 (hr) | Ekopipam za liječenje touretteovog sindroma | |
| PH12019502767A1 (en) | Oral pharmaceutical formulations of remogliflozin | |
| JP2016528283A5 (enExample) |